Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?

Top-Thema

08:24 Uhr
Aktien Frankfurt Ausblick: Trumps gescheiterte Gesundheitsreform belastet

Active Biotech AB Year-end report January - December 2016

Donnerstag, 16.02.2017 08:30

Laquinimod

  • The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
  • The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
  • The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
  • Orphan Drug Designation granted in the US by the FDA ("US Food and Drug Administration")  for laquinimod for the treatment of Huntington's disease

ANYARA     

  • A licensing agreement has been entered into with NeoTX Therapeutics Ltd

Tasquinimod, Paquinimod and SILC

  • Out-licensing activities are continuing
  • The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
  • Product patent for SILC substances granted by the European Patent Office

New share issue 

  • Rights issue implemented in fourth quarter generating proceeds of SEK 53.7 M for the company after issue expenses

Financial summary

SEK M Oct - Dec   Jan - Dec
  2016 2015 2016 2015
Net sales 7.1 5.0 19.0 16.3
Operating loss -13.5 -28.2 -55.1 -177.9
Loss for the period -14.8 -40.8 -59.6 -193.5
Loss per share, before and after dilution (SEK) -0.16 -0.45 -0.65 -2.13
Cash and cash equivalents     77.7 103.6
         
  • Operating costs for full-year 2016 reduced by 62% (SEK 120.1 M) compared with 2015
     
  • Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

For further information, please contact:     

  Tomas Leanderson, President and CEO
  Tel: +46 (0) 46 19 20 95

 

  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44

 
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
   

The report is also available at www.activebiotech.com.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire